Friday, June 19, 2015

Faruqi & Faruqi Investigation: Kythera Biopharmaceuticals, Inc.

KYTHERA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over the Proposed Sale of the Company to Allergan plc.

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc. (“Kythera” or the “Company”) (NasdaqGS: KYTH) for potential breaches of fiduciary duties in connection with the sale of the Company to Allergan plc. for approximately $2.1 billion.  The Company’s stockholders will only receive approximately $75 per share for each share of Kythera common stock they own. The fixed-value transaction consideration will be payable 80 percent in cash and 20 percent in new Allergan shares issued to Kythera shareholders. However, at least one analyst has set a price target of $85.00 for shares of the Company.
If you own common stock in Kythera and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact F&F's Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

No comments:

Post a Comment